上海医药
(601607)
| 流通市值：467.47亿 | | | 总市值：621.52亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 222,963,979,674.49 | 147,469,729,395.2 | 75,261,732,476.16 | 283,579,600,562.98 |
| 营业总成本 | 216,372,977,724.38 | 142,616,534,850.19 | 72,826,169,493.52 | 276,283,476,928.98 |
| 其他经营收益 | | | | |
| 营业利润 | 7,572,312,133.17 | 5,639,763,113.89 | 2,414,466,591.54 | 9,942,085,632.77 |
| 利润总额 | 7,556,123,525.19 | 5,631,382,957.72 | 2,419,194,917.43 | 9,819,804,517.25 |
| 净利润 | 5,766,331,854.25 | 4,341,656,313.04 | 1,850,105,907.45 | 6,973,717,681.49 |
| 每股收益 | | | | |
| 其他综合收益 | 13,712,476.64 | -33,890,811.1 | -16,777,788.77 | 7,600,140.48 |
| 综合收益总额 | 5,780,044,330.89 | 4,307,765,501.94 | 1,833,328,118.68 | 6,981,317,821.97 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 189,240,724,921.31 | 188,381,450,861.08 | 182,841,443,118.25 | 180,463,695,237.78 |
| 非流动资产: | | | | |
| 非流动资产合计 | 52,806,579,695.89 | 52,387,967,588.15 | 52,528,040,569.99 | 52,685,071,529.43 |
| 资产总计 | 242,047,304,617.2 | 240,769,418,449.23 | 235,369,483,688.24 | 233,148,766,767.21 |
| 流动负债: | | | | |
| 流动负债合计 | 140,510,150,261.59 | 140,421,743,446.62 | 136,508,633,684.03 | 135,198,106,270.5 |
| 非流动负债: | | | | |
| 非流动负债合计 | 7,611,782,923.73 | 7,561,895,183.85 | 7,393,331,753.76 | 8,163,366,773.11 |
| 负债合计 | 148,121,933,185.32 | 147,983,638,630.47 | 143,901,965,437.79 | 143,361,473,043.61 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 79,343,843,010.25 | 78,347,955,897.37 | 77,301,063,537.24 | 75,891,327,824.17 |
| 股东权益合计 | 93,925,371,431.88 | 92,785,779,818.76 | 91,467,518,250.45 | 89,787,293,723.6 |
| 负债和股东权益合计 | 242,047,304,617.2 | 240,769,418,449.23 | 235,369,483,688.24 | 233,148,766,767.21 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 235,566,793,853.49 | 156,719,929,875.21 | 75,639,259,982.76 | 313,764,093,844.75 |
| 经营活动现金流出小计 | 230,219,972,745.52 | 152,270,420,627.11 | 76,648,954,356.89 | 307,609,892,465.38 |
| 经营活动产生的现金流量净额 | 5,346,821,107.97 | 4,449,509,248.1 | -1,009,694,374.13 | 6,154,201,379.37 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 44,193,992,978.52 | 26,670,333,955.6 | 6,785,650,960.8 | 67,019,527,857.9 |
| 投资活动现金流出小计 | 44,195,737,127.82 | 26,276,737,562.32 | 7,072,423,289.23 | 71,001,757,513.6 |
| 投资活动产生的现金流量净额 | -1,744,149.3 | 393,596,393.28 | -286,772,328.43 | -3,982,229,655.7 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 54,326,721,495.98 | 38,677,364,369.03 | 23,291,679,591.76 | 69,567,844,851.26 |
| 筹资活动现金流出小计 | 59,470,918,445.75 | 39,625,754,415.63 | 23,139,338,110.41 | 75,219,613,229.84 |
| 筹资活动产生的现金流量净额 | -5,144,196,949.77 | -948,390,046.6 | 152,341,481.35 | -5,651,768,378.58 |
| 汇率变动对现金及现金等价物的影响 | -4,468,383.79 | -8,971,209.55 | -8,778,258.86 | -3,115,599.14 |
| 现金及现金等价物净增加额 | 196,411,625.11 | 3,885,744,385.23 | -1,152,903,480.07 | -3,482,912,254.05 |
| 期末现金及现金等价物余额 | 28,594,772,165.93 | 32,284,104,926.05 | 27,245,457,060.75 | 28,398,360,540.82 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 3,885,744,385.23 | - | -3,482,912,254.05 |
最新报告期：2026-11-02| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中金公司 | 夏璐,张琎,朱言音 | 1.54 | 1.61 | -- | 2026-11-02 |
| 中国银河 | 程培 | 1.46 | 1.60 | 1.77 | 2026-10-31 |
| 平安证券 | 叶寅,倪亦道,王钰畅 | 1.42 | 1.58 | 1.72 | 2026-09-30 |
| 中信建投 | 刘若飞,沈兴熙,贺菊颖 | 1.41 | 1.51 | 1.65 | 2026-09-06 |
| 中金公司 | 夏璐,张琎,朱言音 | 1.62 | 1.72 | -- | 2026-09-01 |